JP2020535138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535138A5 JP2020535138A5 JP2020516798A JP2020516798A JP2020535138A5 JP 2020535138 A5 JP2020535138 A5 JP 2020535138A5 JP 2020516798 A JP2020516798 A JP 2020516798A JP 2020516798 A JP2020516798 A JP 2020516798A JP 2020535138 A5 JP2020535138 A5 JP 2020535138A5
- Authority
- JP
- Japan
- Prior art keywords
- bound
- alpha
- lys
- fatty
- diacid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims 46
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims 40
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 30
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 claims 30
- 208000008589 Obesity Diseases 0.000 claims 23
- 239000000556 agonist Substances 0.000 claims 23
- 235000020824 obesity Nutrition 0.000 claims 23
- 125000001931 aliphatic group Chemical group 0.000 claims 22
- 206010012601 diabetes mellitus Diseases 0.000 claims 22
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 20
- 208000030159 metabolic disease Diseases 0.000 claims 17
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 16
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 14
- 239000002253 acid Substances 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims 10
- 229930195729 fatty acid Natural products 0.000 claims 10
- 239000000194 fatty acid Substances 0.000 claims 10
- 150000004665 fatty acids Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- CDUUKBXTEOFITR-BYPYZUCNSA-N 2-methyl-L-serine Chemical compound OC[C@@]([NH3+])(C)C([O-])=O CDUUKBXTEOFITR-BYPYZUCNSA-N 0.000 claims 9
- 229960005190 phenylalanine Drugs 0.000 claims 9
- 229940024606 amino acid Drugs 0.000 claims 8
- 150000001413 amino acids Chemical group 0.000 claims 8
- ZTTWHZHBPDYSQB-LBPRGKRZSA-N (2s)-2-amino-3-(1h-indol-3-yl)-2-methylpropanoic acid Chemical compound C1=CC=C2C(C[C@@](N)(C)C(O)=O)=CNC2=C1 ZTTWHZHBPDYSQB-LBPRGKRZSA-N 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 6
- HYOWVAAEQCNGLE-JTQLQIEISA-N alpha-methyl-L-phenylalanine Chemical compound OC(=O)[C@](N)(C)CC1=CC=CC=C1 HYOWVAAEQCNGLE-JTQLQIEISA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 5
- -1 L-Met sulfone Chemical class 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 108010089308 Insulin Detemir Proteins 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 208000016097 disease of metabolism Diseases 0.000 claims 3
- 208000004104 gestational diabetes Diseases 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 229960003948 insulin detemir Drugs 0.000 claims 2
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 claims 2
- 108010063919 Glucagon Receptors Proteins 0.000 claims 1
- 102100040890 Glucagon receptor Human genes 0.000 claims 1
- 108010057186 Insulin Glargine Proteins 0.000 claims 1
- 108010065920 Insulin Lispro Proteins 0.000 claims 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims 1
- UCUNFLYVYCGDHP-UHFFFAOYSA-N L-methionine sulfone Natural products CS(=O)(=O)CCC(N)C(O)=O UCUNFLYVYCGDHP-UHFFFAOYSA-N 0.000 claims 1
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 1
- 229960002869 insulin glargine Drugs 0.000 claims 1
- 108700039926 insulin glulisine Proteins 0.000 claims 1
- 229960000696 insulin glulisine Drugs 0.000 claims 1
- 229960002068 insulin lispro Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023032146A JP2023071869A (ja) | 2017-09-25 | 2023-03-02 | グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト |
| JP2023144460A JP2023171744A (ja) | 2017-09-25 | 2023-09-06 | グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762562674P | 2017-09-25 | 2017-09-25 | |
| US62/562,674 | 2017-09-25 | ||
| PCT/US2018/052124 WO2019060660A1 (en) | 2017-09-25 | 2018-09-21 | CO-AGONISTS WITH EXTENDED ACTION OF GLUCAGON AND GLP-1 RECEPTORS |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023032146A Division JP2023071869A (ja) | 2017-09-25 | 2023-03-02 | グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト |
| JP2023144460A Division JP2023171744A (ja) | 2017-09-25 | 2023-09-06 | グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020535138A JP2020535138A (ja) | 2020-12-03 |
| JP2020535138A5 true JP2020535138A5 (enExample) | 2021-10-07 |
Family
ID=65810991
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516798A Pending JP2020535138A (ja) | 2017-09-25 | 2018-09-21 | グルカゴンおよびｇｌｐ−１受容体の長時間作用型コアゴニスト |
| JP2023032146A Pending JP2023071869A (ja) | 2017-09-25 | 2023-03-02 | グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト |
| JP2023144460A Pending JP2023171744A (ja) | 2017-09-25 | 2023-09-06 | グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023032146A Pending JP2023071869A (ja) | 2017-09-25 | 2023-03-02 | グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト |
| JP2023144460A Pending JP2023171744A (ja) | 2017-09-25 | 2023-09-06 | グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11566057B2 (enExample) |
| EP (1) | EP3700550A4 (enExample) |
| JP (3) | JP2020535138A (enExample) |
| KR (1) | KR102505628B1 (enExample) |
| CN (1) | CN111132690A (enExample) |
| AU (1) | AU2018338184B2 (enExample) |
| BR (1) | BR112020005841A8 (enExample) |
| CA (2) | CA3076496A1 (enExample) |
| MA (1) | MA50474A (enExample) |
| MX (1) | MX2020003217A (enExample) |
| WO (1) | WO2019060660A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021078912A1 (en) * | 2019-10-22 | 2021-04-29 | Nuritas Limited | Treatment of non-alcoholic fatty liver disease |
| EP3842060A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled lactam co-agonists of the glucagon and glp-1 receptors |
| EP3842061A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled triazole co-agonists of the glucagon and glp-1 receptors |
| EP3842449A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled olefin co-agonists of the glucagon and glp-1 receptors |
| US12122817B2 (en) * | 2020-09-22 | 2024-10-22 | Serpentide Inc. | Long-lasting GLP1 analogue drug for type-2 diabetes |
| IL304214B2 (en) | 2021-01-20 | 2025-01-01 | Viking Therapeutics Inc | Compositions and methods for treating metabolic and liver disorders |
| EP4376871A1 (en) * | 2021-07-30 | 2024-06-05 | Boehringer Ingelheim International GmbH | Dose regimen for long-acting glp1/glucagon receptor agonists |
| KR102873595B1 (ko) | 2021-09-15 | 2025-10-22 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 장애의 치료를 위한 조성물 및 방법 |
| CN117586373A (zh) * | 2022-08-10 | 2024-02-23 | 成都奥达生物科技有限公司 | 一种长效双激动剂化合物 |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2024252366A1 (en) * | 2023-06-09 | 2024-12-12 | Sun Pharmaceutical Industries Limited | Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US6852690B1 (en) | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| GB0308801D0 (en) * | 2003-04-16 | 2003-05-21 | Celltech R&D Ltd | Chemical compounds |
| PL1891105T3 (pl) | 2005-06-13 | 2012-09-28 | Imperial Innovations Ltd | Analogi oksyntomoduliny i ich wpływ na zachowania żywieniowe |
| JP6017754B2 (ja) | 2007-02-15 | 2016-11-02 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴン／ｇｌｐ−１受容体コアゴニスト |
| CA2728284C (en) | 2008-06-17 | 2019-09-10 | Richard D. Dimarchi | Glucagon/glp-1 receptor co-agonists |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| EP2723766A4 (en) | 2011-06-22 | 2015-05-20 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
| PH12013502671A1 (en) | 2011-06-22 | 2022-04-08 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
| CA3093383A1 (en) | 2014-10-24 | 2016-04-28 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
| EP3377521A4 (en) * | 2015-10-27 | 2019-05-01 | Merck Sharp & Dohme Corp. | LONG-ACTING CO AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS |
| EP3430033A4 (en) * | 2016-03-18 | 2019-11-20 | Merck Sharp & Dohme Corp. | CONJUGATES OF INSULIN-INCRETIN |
-
2018
- 2018-09-21 MX MX2020003217A patent/MX2020003217A/es unknown
- 2018-09-21 EP EP18858623.4A patent/EP3700550A4/en active Pending
- 2018-09-21 JP JP2020516798A patent/JP2020535138A/ja active Pending
- 2018-09-21 WO PCT/US2018/052124 patent/WO2019060660A1/en not_active Ceased
- 2018-09-21 CA CA3076496A patent/CA3076496A1/en active Pending
- 2018-09-21 AU AU2018338184A patent/AU2018338184B2/en active Active
- 2018-09-21 BR BR112020005841A patent/BR112020005841A8/pt not_active Application Discontinuation
- 2018-09-21 KR KR1020207011622A patent/KR102505628B1/ko active Active
- 2018-09-21 US US16/643,881 patent/US11566057B2/en active Active
- 2018-09-21 CN CN201880062111.1A patent/CN111132690A/zh active Pending
- 2018-09-21 CA CA3220650A patent/CA3220650A1/en active Pending
- 2018-09-21 MA MA050474A patent/MA50474A/fr unknown
-
2023
- 2023-03-02 JP JP2023032146A patent/JP2023071869A/ja active Pending
- 2023-09-06 JP JP2023144460A patent/JP2023171744A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020535138A5 (enExample) | ||
| TWI767095B (zh) | 腸促胰島素(incretin)類似物及其用途 | |
| TWI810606B (zh) | Gip/glp1共促效劑化合物 | |
| JP7541600B2 (ja) | Ｇｉｐアゴニスト化合物及び方法 | |
| US11111285B2 (en) | Glucagon-GLP-1-GIP triple agonist compounds | |
| ES2502218T3 (es) | Análogos de glucagón | |
| TWI670281B (zh) | Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法 | |
| US20150250882A1 (en) | Fatty Acid Acylated Amino Acids for Growth Hormone Delivery | |
| US20110286982A1 (en) | Glucagon analogues | |
| JP2013537879A (ja) | 部位特異的ｐｅｇ修飾エキセンディン−４アナログ及びその使用 | |
| KR20040058324A (ko) | 경비흡수용 의약 조성물 | |
| JP2012529463A5 (enExample) | ||
| AU2021229233A1 (en) | ELP fusion proteins for controlled and sustained release | |
| EP3452021A1 (en) | Elp fusion proteins for controlled and sustained release | |
| HRP20211575T1 (hr) | Fuzijski proteini za liječenje metaboličkih poremećaja | |
| HRP20201353T1 (hr) | Agonisti glukagonskog receptora | |
| RS57531B1 (sr) | Derivati eksendina-4 kao dualni glp1/gip- ili trigonalni glp1/gip/glukagon agonisti | |
| AU2018338184A1 (en) | Long-acting co-agonists of the glucagon and GLP-1 receptors | |
| CN109996557A (zh) | 作为肽类glp1/胰高血糖素/gip受体激动剂的新化合物 | |
| CA2965560A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| TW201018479A (en) | Amylin derivatives | |
| JP2024521398A (ja) | 肥満及び肥満関連障害の治療 | |
| JP2020503367A (ja) | Ｐａｃ１受容体作動薬（ｍａｘｃａｐ）及びその用途 | |
| US20250243255A1 (en) | Crf2 receptor agonists and their use in therapy | |
| Linderoth et al. | GLP‐1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity |